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Abstract
Background/objectives: Assessing the clinical relevance of non-tuberculous mycobacteria (NTM) isolated from
respiratory samples can be challenging. The epidemiology and pathogenicity of NTM species vary geographically.
We aimed to outline the clinical relevance and associated radiological patterns of NTM species isolated in Belgium.
Methods: We performed a retrospective multicentre analysis of all patients identified from the laboratory database
with > 1 respiratory sample growing NTM from January 2010 through December 2017. We collected clinical,
radiological and microbiological data through medical record review and assessed clinical relevance according to
ATS/IDSA criteria for NTM pulmonary disease (NTM-PD).
Results: Of the 384 unique patients, 60% were male, 56% had a smoking history and 61% had pre-existing lung
disease. Mycobacterium avium complex (MAC), M. gordonae and M. xenopi were the most frequently isolated
species: 53, 15 and 8% respectively. 43% of patients met ATS/IDSA criteria, of whom 28% presented with
fibrocavitary disease. Weight loss, fever, nodular bronchiectatic and fibrocavitary lesions on chest CT, and a positive
acid-fast bacilli (AFB) stain were significantly associated with NTM-PD. The species with the highest pathogenic
potential were M. abscessus (11/12), M. malmoense (6/7) and M. intracellulare (41/64).
Conclusion: In our study, MAC was the most commonly isolated NTM species, but M. abscessus and M. malmoense
showed the highest probability of being clinically relevant. Clinical relevance varied not only by species but also by
radiological findings on chest CT and AFB staining. Clinicians should consider these elements in their treatment
decision making. Prospective data including clinical outcome are needed to provide more robust evidence.
Keywords: Non-tuberculous mycobacteria (NTM), Non-tuberculous mycobacterial pulmonary disease (NTM-PD),
Epidemiology, Radiology
Background
Non-tuberculous mycobacteria (NTM) are ubiquitous in the
natural environment and household water systems [1, 2].
Over 180 different species have been identified, but only 32
have been reported causing human or animal disease [3].
Lung infections (NTM related pulmonary disease or NTM-
PD) account for 90% of NTM related disease. Patients with
pre-existing lung disease like chronic obstructive pulmonary
disease (COPD), cystic fibrosis (CF), and non-CF bronchiec-
tasis are predisposed [4–8]. To a lesser extent NTM can
cause infections of skin, sinuses, lymph nodes, or even lead
to disseminated disease in case of innate or acquired im-
munodeficiency [5, 9].
Worldwide pulmonary isolation of NTM is increasing
and, according to some data, so is the incidence of NTM-
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PD [10–14]. Since NTM-PD is not a reportable disease in
most countries, reliable epidemiological data are scarce.
NTM species vary between countries and regions and
can even change over time, as does their respective
pathogenicity [10, 12, 15–17]. Overall, species from the
Mycobacterium avium complex (MAC) are the most
commonly isolated NTM [12, 15, 18]. M. avium pre-
dominates in North America [12, 13], whereas in
Australia M. intracellulare is more prevalent [19]. In the
Republic of Korea M. intracellulare is the most prevalent
species but M. abscessus is also quite common [20, 21].
In Europe, M. avium and M. intracellulare are almost
equally prevalent, but species other than MAC are also
frequently isolated which can be clinically relevant as
well (M. kansasii, M. xenopi, M. malmoense, ...) [15, 18].
There are marked regional differences in isolation fre-
quency and pathogenic potential of different species[12,
15, 18]. Epidemiological data from Belgium are limited
to isolation frequency without clinical information [17].
Assessing the clinical relevance of respiratory NTM
isolates can be challenging. Intermittent isolation is fre-
quent and spontaneous culture conversion is possible
without harm to the patient. The American Thoracic
Society (ATS) and the Infectious Diseases Society of
America (IDSA) developed diagnostic criteria for NTM-
PD to guide treatment decisions, since objective markers
of disease predicting which patients will develop active
NTM-PD are lacking [4]. These criteria are widely im-
plemented although based on expert opinion and barely
validated [5]. Whether they can be universally applied in
all patient populations remains debatable.
Besides ATS/IDSA criteria, taking into account the
local epidemiology and individual species pathogenicity
can facilitate treatment decision-making. This should be
a well-considered process given the prolonged, poten-
tially toxic and costly multidrug regimens used in NTM-
PD with relatively poor efficacy [4, 5, 7].
We aimed to outline the epidemiology of respiratory
NTM isolates in our region, assess their clinical rele-
vance according to the ATS/IDSA criteria and explore
the possibility of an association between clinical rele-
vance and the radiological pattern on chest CT.
Methods
Design
We performed a multicentre, retrospective cohort study
including all patients with at least one respiratory sample
yielding NTM between January 2010 and December
2017 from three Belgian reference centres: University
Hospitals Leuven, Ghent University Hospital and Stui-
venberg Hospital Antwerp. The ethics committees of all
participating centres granted approval. Informed consent
was waived given the retrospective nature of the study.
Study cohort
Starting from the microbiology database, we searched for
samples positive for NTM of patients aged > 18 years from
January 2010 through December 2017. We only included pa-
tients with respiratory samples defined as sputum, bronchial
wash, mediastinal lymph node biopsy and lung biopsy.
People living with human immunodeficiency virus (HIV)
were excluded because of their different disease presentation.
Data collection
At least one investigator per centre reviewed the electronic
patient record using a standardised clinical report form.
We collected the following data: age, gender, race, comor-
bidities, smoking history, clinical presentation, radiological
features at diagnosis, microbiology (NTM species, acid-fast
bacilli (AFB) staining, co-isolation of Aspergillus fumigatus
species complex and/or Pseudomonas aeruginosa). Clinical
relevance was defined in accordance with ATS/IDSA cri-
teria for NTM-PD i.e. presence of symptoms and radiologic
abnormalities compatible with NTM lung disease and
microbiological confirmation as specified in Table 1. Cases
who did not meet the ATS/IDSA diagnostic criteria were
only considered as respiratory isolation of an NTM without
NTM-PD. For challenging cases a consensus was sought
through an expert panel of 3 senior investigators. Immuno-
deficiency was considered a comorbidity when the patient
suffered from a primary immunodeficiency or haemato-
logical malignancy, when he was treated with immunosup-
pressive drugs (systemic corticosteroids, tumor necrosis
alpha inhibitors, cytostatic agents) or had a solid organ
transplant or bone marrow transplant [9]. Radiological fea-
tures were defined as ‘fibrocavitary’ when fibrotic and/or
cavitary lesions were present and ‘nodular bronchiectatic’
when multiple small nodules <5mm and/or bronchiectasis
were found. All other anomalies were grouped as ‘other’.
Respiratory samples were incubated on liquid and/or solid
mycobacterial culture media. After ruling out the presence
of M. tuberculosis complex (MTBc) using a targeted PCR
Table 1 Clinical and microbiological criteria for diagnosis of
NTM-PD as proposed in the 2007 ATS/IDSA statement
Clinical:
- Pulmonary symptoms with nodular or cavitary opacities on chest
radiograph or HRCT that show multifocal bronchiectasis with multiple
small nodules.
- AND sufficient exclusion of other diseases/ diagnoses.
Microbiological:
- Positive sputum culture results of at least two separately expectorated
samples.
- OR positive culture results from at least one bronchial wash or lavage.
- OR transbronchial or other lung biopsy with mycobacterial
histopathological features AND positive culture for NTM on biopsy or
on at least one or more sputum samples or bronchial washing.
Adapted from Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C,
Gordin F, et al. An official ATS/IDSA statement: Diagnosis, treatment, and
prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care
Med. 2007;175(4):367–416
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amplifying the MTBc-specific IS6110, species identification
was performed at the national reference laboratory for
mycobacteriology (Sciensano, Brussels, Belgium) from posi-
tive cultures and was based on a combination of techniques
targeting the 16S rRNA gene. PCR-based techniques in-
cluded Inno-Lipa Mycobacteria v2 (Innogenetics, Gent,
Belgium) and the Genotype Mycobacterium CM (Hain
Lifescience GmbH, Nehren, Germany) assays. When these
tests did not provide a species identification, sequencing of
the 16S rRNA gene was performed as previously described
[22]. Unfortunately, species and sub-species differentiation
was not always achieved within the MAC and M. chelonae-
abscessus complex groups.
Statistics
Continuous variables were described as medians and inter-
quartile ranges (IQR) and categorical variables as absolute
numbers and percentages of total. We compared cases with
NTM-PD to cases not fulfilling the ATS/IDSA criteria using
the Mann-Whitney U test for not-normally distributed con-
tinuous variables (age) and χ2 or Fisher’s exact test as appro-
priate (using odds ratios (OR) and 95% confidence intervals
(CI 95%)) for dichotomous categorical variables. A two-sided
error level of p < 0.05 was considered statistically significant.
Multivariable logistic regression modelling was done includ-
ing all factors associated with the outcome in univariate ana-
lysis. Starting from the full model including all co-variates, a
backward stepwise selection process was performed retaining
in the final model only variables with a p-value < 0.05. We
checked for interactions with identified risk factors for those
co-variates that seemed most plausible (gender and history
of previous NTM) first and conducted a stratified Mantel-
Haenszel analysis and tested for homogeneity of the ORs
across the strata. For those factors with statistically significant
(p-value < 0.05) heterogeneity (effect modification) an inter-
action term was included in the logistic regression model.
However, none were retained (as statistically non-significant)
in the final analysis. Statistical analysis was computed with
SPSS version 25.0 (SPSS, Inc., Chicago, IL, USA) and Stata
version 15 (StataCorp, Texas, USA).
Results
Of the 508 unique patients in whom NTM were isolated, we
identified 384 patients with at least one NTM positive
Fig. 1 Selection of our study cohort
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respiratory sample (Fig. 1). Figure 2 shows the evolution over
time of NTM respiratory isolates and NTM-PD cases. We
noted an increase in the number of respiratory NTM isolates
from 51 in 2010 to 75 new isolations (in unique patients) in
2017, whereas the number of new cases of NTM-PD
remained approximately stable during our study period.
Over 90% of the patients in our cohort were seen by a pul-
monologist. Forty-three percent (165/384) of the patients ful-
filled ATS/IDSA criteria for NTM-PD. Table 2 presents
baseline demographic, clinical, radiological and microbio-
logical characteristics of the total cohort as well as by fulfil-
ment of ATS/IDSA criteria. Over half of patients were
current or ex-smokers (56.5%), 60.4% were male, and the
majority were of Caucasian descent (95.8%), with a median
(IQR) age of 65 (54–74) years. Pre-existing lung disease was
present in 61%, most commonly COPD/emphysema (41.4%)
and non-CF bronchiectasis (15.6%). Over 20% was immuno-
compromised to some extent. Besides previous episodes of
NTM-PD and non-CF bronchiectasis, no other comorbidi-
ties were found to be significantly associated with NTM-PD
after univariate analysis. These co-variates were not signifi-
cant in multivariate analysis.
Cough (72.4%), sputum expectoration (50%) and dys-
pnoea (48.4%) were the most frequently reported present-
ing symptoms. Fever (17.7%), night sweats (7.8%), fatigue
(28.4%), weight loss (28.1%), and hemoptysis (16.4%) were
less common. In univariate analysis, fever (24.2%), night
sweats (12.1%), fatigue (38.2%), cough (81.8%), weight loss
(43%) and haemoptysis (21.2%) were more commonly as-
sociated with NTM-PD cases than with cases not fulfilling
ATS/IDSA criteria (Table 2).
Fibrocavitary lesions were present in 63 (16.4%) patients,
whereas 188 (49%) patients had nodular bronchiectatic
changes; 16 (4.2%) had a normal chest CT. Fibrocavitary
lesions were associated with NTM-PD (OR 4.45 [2.44–
8.12]) as were nodular bronchiectatic lesions (OR 2.50
[1.64–3.81]).
Twenty percent of patients had positive AFB staining,
which correlated significantly with ATS/IDSA criteria
(OR 9.28 [4.96–17.34]). In univariate analysis (but not in
multivariate analysis) co-isolation of A. fumigatus
seemed significantly associated with NTM-PD cases (OR
2.32 [1.37–3.93]). This was not the case for co-isolation
of P. aeruginosa (OR 1.07 [0.60–1.90]) (Table 2).
Multivariate analysis revealed that only symptoms like
fever (OR 2.26 [1.12–4.56]) and weight loss (OR 2.47
[1.42–4.31]); fibrocavitary (OR 11.0 [4.74–25.57]) and
nodular bronchiectatic findings (OR 7.34 [3.87–13.91]) on
chest CT as well as positive AFB-staining (OR 5.20 [2.60–
10.42]) were independently associated with NTM-PD.
MAC was the commonest in terms of isolates in gen-
eral and clinically relevant isolates (53.4%). On individual
species level, M. avium (25%) was the most frequently
isolated species followed by M. intracellulare (16.7%),
M. gordonae (14.6%) and M. xenopi (7.6%). Among the
clinically relevant isolates (NTM-PD), again MAC was
predominant (67.3%); M. avium (31.5%), M. intracellu-
lare (24.8%), M. xenopi (8.5%) and M. abscessus (6.7%)
being the most frequently encountered pathogens in
NTM-PD subjects (Fig. 3).
Figure 4 illustrates the pathogenic potential of the in-
dividual species according to ATS/IDSA criteria. M.
Fig. 2 New isolates and diagnoses per year. Histogram with annual detection of new patients with an NTM-yielding respiratory sample (blue) and
the annual incidence of new cases of NTM-PD (orange)
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szulgai (2/2) was rare but very pathogenic, followed by
the more common M. abscessus (11/12), M. malmoense
(6/7), M. intracellulare (41/64), M. kansasii (7/11), M.
avium (52/96) and M. xenopi (14/29). M. gordonae (1/
56), M. chelonae (1/9) and M. fortuitum (2/15) were
rarely considered clinically relevant.
Most NTM-PD cases caused by M. kansasii (57.1%),
M. malmoense (83.3%) and M. xenopi (71.4%) presented
with fibrocavitary disease. In contrast, the majority of
cases of M. abscessus related NTM-PD presented with
nodular bronchiectatic disease (81.8%). This also applies
to the majority of cases involving MAC; however, cases
Table 2 Clinical characteristics of the 384 subjects of our study cohort by ATS/IDSA criteria
Total cohort (n = 384) ATS/IDSA + (n = 165) ATS/IDSA - (n = 219) ORa [CI 95%] aORb [CI 95%]
Demography n (%) n (%) n (%)
Median age in years (IQR)c 65 (54–74) 64 (52–74) 67 (55–75) – –
Male 232 (60.4%) 94 (57%) 138 (63%) 0.78 [0.51–1.17] –
Smoking historyd 217 (56.5%) 96 (58.2%) 121 (55.3%) 1.03 [0.68–1.57] –
Comorbiditye
Non-CF bronchiectasis 60 (15.6%) 33 (20%) 27 (12.3%) 1.74 [1.00–3.03] –
Cystic fibrosis 24 (6.3%) 10 (6.1%) 14 (6.4%) 0.93 [0.40–2.14] –
COPD/emphysema 159 (41.4%) 69 (41.8%) 90 (41.1%) 1.00 [0.66–1.51] –
Previous NTM disease 31 (8.1%) 23 (13.9%) 8 (3.7%) 4.19 [1.82–9.63] –
Previous TB disease 32 (8.3%) 12 (7.3%) 20 (9.1%) 0.76 [0.36–1.61] –
Pulmonary aspergillosis 16 (4.2%) 7 (4.2%) 9 (4.1%) 1.01 [0.37–2.78] –
Gastroesophageal reflux 28 (7.3%) 8 (4.8%) 20 (9.1%) 0.50 [0.21–1.16] –
Active malignancy 63 (16.4%) 28 (17%) 35 (16%) 1.05 [0.61–1.81] –
Immunodeficiency 91 (23,7%) 44 (26,7%) 47 (21.5%) 1.30 [0.81–2.09] –
Transplantation 22 (5.7%) 9 (5.5%) 13 (5.9%) 0.90 [0.37–2.15] –
Other 127 (33.1%) 52 (31.5%) 75 (34.2%) 0.86 [0.56–1.33] –
Symptomatologyf
Fever 68 (17.7%) 40 (24.2%) 28 (12.8%) 2.11 [1.24–3.61] 2.26 [1.12–4.56]
Night sweats 30 (7.8%) 20 (12.1%) 10 (4.6%) 2.80 [1.27–6.16] –
Fatigue/malaise 109 (28.4%) 63 (38.2%) 46 (21%) 2.24 [1.43–3.53] –
Sputum 192 (50%) 90 (54.5%) 102 (46.6%) 1.31 [0.87–1.96] –
Chest pain 41 (10.7%) 20 (12.1%) 21 (9.6%) 1.26 [0.66–2.41] –
Cough 278 (72.4%) 135 (81.8%) 143 (65.3%) 2.20 [1.35–3.59] –
Dyspoea 186 (48.4%) 77 (46.7%) 109 (49.8%) 0.84 [0.56–1.25] –
Weight loss 108 (28.1%) 71 (43%) 37 (16.9%) 3.59 [2.25–5.74] 2.47 [1.42–4.31]
Hemoptysis 63 (16.4%) 35 (21.2%) 28 (12.8%) 1.78 [1.03–3.07] –
Other 31 (8.1%) 11 (6.7%) 20 (9.1%) 0.69 [0.32–1.48] –
Radiology (chest CT)g
Fibrocavitary lesions 63 (16.4%) 46 (27.9%) 17 (7.8%) 4.45 [2.44–8.12] 11.0 [4.74–25.57]
Nodular bronchiectatic lesions 188 (49%) 103 (54.8%) 85 (38.8%) 2.50 [1.64–3.81] 7.34 [3.87–13.91]
Other 124 (32.3%) 15 (12.1%) 109 (49.8%) 0.094 [0.052–0.17] –
Microbiology
AFB staining positive 78 (20.3%) 64 (38.8%) 14 (6.4%) 9.28 [4.96–17.34] 5.20 [2.60–10.42]
Pseudomonas aeruginosah 54 (14.1%) 24 (14.5%) 30 (13.7%) 1.07 [0.60–1.90] –
Aspergillus fumigatush 70 (18.2%) 42 (25.5%) 28 (12.8%) 2.32 [1.37–3.93] –
Frequencies are given as absolute numbers (percentage of column total). aOdds ratio and 95% confidence interval calculated from univariate analysis. Statistically
significant differences in univariate analysis (two-sided p < 0.05) marked in bold. bAdjusted odds ratio based on results from multivariate analysis. cAge as median
age (IQR) in years, no statistically significant difference with Mann-Whitney U test. Missing information for: d12, f6, g9 patients respectively. hFound as co-isolates
with NTM
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with MAC presenting with fibrocavitary lesions had a
higher relative frequency of NTM-PD. When presenting
with fibrocavitary changes on chest CT most isolated
NTM were clinically significant (46/63; 73%). As for
nodular bronchiectatic lesions, this was less pronounced
(103/188, 55%). When neither fibrocavitary nor nodular
bronchiectatic lesions were present on chest CT, the iso-
lated NTM was most often not considered clinically
relevant (15/124; 12%) with few exceptions as presented
in Fig. 5. As an example, M. xenopi was clinically
relevant in 14 of 29 (48%) isolates. When associated with
fibrocavitary lesions clinical relevance increased to 10/14
(71%), whereas in the presence of nodular bronchiectatic
disease this was 3/6 (50%). When neither were present,
M. xenopi isolation was mostly not relevant (only 1/9).
Discussion
To the best of our knowledge, the present study is the first
to describe clinical and radiographic features in relation to
species-specific pathogenic potential of respiratory NTM
Fig. 3 Frequencies of individual species in NTM isolates and diagnoses of NTM-PD. The upper pie chart shows all patients. The lower pie chart
shows only patients meeting ATS/IDSA criteria for NTM-PD. *“Other NTM” encompasses all other, rarer isolates < 1% of total. Upper pie chart: M.
cellatum; M. florentinum; M. gilvum; M. holsaticum; M. lentiflavum; M. wolinsky/jacuzzi; M. noviomagense; M. novocastrense; M. peregrinum; M. terrae
complex. Lower pie chart: M. cellatum; M. florentinum; M. noviomagense; M. peregrinum. **NOS: MAC not further identified and reported as ‘MAC’
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Fig. 4 Ratio of clinical significance. Clinical significance per species; presented as a percentage based on the number of cases meeting ATS/IDSA
criteria for NTM-PD and the total number of isolates per species. MAC and M. chelonae/abscessus complex, not further specified, were regarded
separately. On the left, species of low virulence are found and on the right the most pathogenic species. Figure concept van Ingen et al., Thorax
2009, with permission
Fig. 5 Ratio of clinical significance sorted by radiological presentation. Clinical significance per species; presented as a percentage based on the
number of cases meeting ATS/IDSA criteria for NTM-PD and the total number of isolates per species. MAC and M. chelonae/abscessus complex,
not further specified, were regarded separately. On the left, species of low virulence are found and on the right the most pathogenic species. In
the upper bar cases with fibrocavitary changes are depicted, in the middle bar cases with nodular bronchiectatic changes are presented and in
the lower bar cases with neither fibrocavitary nor nodular bronchiectatic changes are shown. Figure concept van Ingen et al., Thorax 2009,
with permission
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isolates in Belgium. The frequency of NTM-PD remained
stable over an 8-year time period in the three participating
reference centres, despite increasing isolation frequency.
NTM isolates were clinically significant in 43% of the pa-
tients. Symptoms like fever and weight loss, fibrocavitary
and nodular bronchiectatic lesions on chest CT and a
positive AFB stain were significantly associated with
NTM-PD. MAC was the commonest mycobacterial isolate
and pathogen in our cohort.
Although there was an annual increase in new NTM iso-
lates, numbers of newly diagnosed NTM-PD remained
stable. This evolution over time is in line with study find-
ings in Denmark and the Netherlands [23, 24], whereas re-
ports from the UK, Germany, Canada and the USA report
an increasing incidence of NTM-PD [11, 13, 14, 25, 26].
The increasing isolation of NTM from respiratory samples
may be partly due to a rising awareness and screening, but
may also be explained by environmental factors or an age-
ing population with more comorbidities and predisposition
to NTM-PD. However, the real incidence of NTM-PD re-
mains uncertain since NTM-PD is not a reportable disease
in most countries. Therefore, longitudinal and prospective
registries could be very informative concerning the true in-
cidence of NTM-PD.
Less than half of pulmonary NTM isolates are consid-
ered clinically relevant according to the ATS/IDSA cri-
teria. Over 40% of patients in our cohort met the ATS/
IDSA criteria, in contrast to lower reported numbers of
25–33% in similar studies from the Netherlands, the UK
and South Korea [23, 27, 28]. This might be explained by
the nature of referrals and underlying disease severity.
Patients in our study cohort were predominantly male
and middle-aged, which is in concordance with some
previous reports [6, 23] but in contrast to reports from
the US and Japan where a different morphotype (white,
middle-aged females) is described [12, 29, 30]. Pre-
existing lung disease such as COPD and bronchiectasis
were the most common comorbidities. Chronic respira-
tory disease is an important risk factor for NTM-PD, mak-
ing it a pulmonologists issue: it has been associated with a
16-fold increased risk in a Danish population-based case-
control study [31]. The finding was confirmed by Marras
et al., reporting a nine times higher incidence of NTM-PD
in COPD [8]. Closer surveillance for NTM in patients
with pulmonary disease may be warranted.
Diagnosis of NTM-PD according to ATS-IDSA criteria
can be challenging as symptoms are often nonspecific
and partly overlapping with underlying illness. Fever,
night sweats and weight loss tend to be present in ad-
vanced NTM-PD [4]. Similarly in our study, fever and
weight loss were independently associated with NTM-
PD. Cough and fatigue also tended to be more fre-
quently reported in patients with NTM-PD similar to
findings from Aksamit et al., but these are rather non-
specific symptoms which are often related to underlying
diseases [4, 29]. The presence of nodular bronchiectatic
lesions and especially fibrocavitary lesions on chest CT
were significantly associated with NTM-PD. In the
absence of either fibrocavitary or nodular bronchiectatic
lesions, isolates were mostly not clinically relevant, a
finding corroborating the ATS/IDSA criteria. Fibrocavi-
tary lesions are a marker of severe NTM-PD with worse
prognosis [4, 32, 33]. Similarly, the majority of patients
in our cohort with respiratory samples positive on AFB
staining suffered from NTM-PD. This is in line with
previous studies, where AFB stain positivity has been as-
sociated with a higher bacterial burden, more severe
NTM-PD and poor outcome [5, 33]. A. fumigatus co-
isolation was also associated with NTM-PD in univariate
analysis as suggested in previous studies by Kunst et al.
and Provoost et al. [34, 35]. The value of this finding re-
mains unclear as in multivariate analysis this factor was
no longer deemed significant. Is A. fumigatus co-isolation
a risk factor or the consequence of NTM-PD? It could
also be related to underlying lung disease or immunosup-
pression [34–36]. Prospective studies or registries could
identify true risk factors or indicators which could help re-
fining the current ATS/IDSA criteria for establishing the
diagnosis of NTM-PD.
With MAC accounting for more than half of the isolates,
its prevalence in our study is comparable with a 2008 report
from the Belgian national reference lab in which 38% of all
isolates were MAC [18]. In other European studies, MAC
was the predominant species as well, although regional dif-
ferences were noted [15, 18]. M. avium, M. intracellulare,
M. gordonae and M. xenopi were the most frequently
isolated species, in accordance with a national report by
Soetaert et al. where M. avium, M. intracellulare and M.
xenopi accounted for 20, 21 and 15% of all (pulmonary and
other) isolates respectively [17]. Of note, the same group
previously showed that M. chimaera was frequently mis-
identified as M. intracellulare [22]. In our report we did not
systematically re-evaluate these very closely related species.
The difference for M. xenopi could be explained as our
cohort did not properly cover the coast nor the southern
half of the country which have a distinct environment. M.
xenopi is a species mainly found in Europe with high con-
centrations in Southern Europe and along the English
Channel [18, 37]. Accounting for only 3% of isolates,
M. abscessus was rather rare which is similar to other
European reports [12, 15]. Prevalence of M. abscessus
isolates is substantially higher in Asia (16%) and Oceania
(12%). These differences can be explained by different en-
vironmental factors and/or changing mycobacterial fauna
over time [12, 15, 17, 18].
MAC was the main culprit (67.3%) for NTM-PD in this
study cohort (Fig. 3). The position of MAC as the main
cause of NTM-PD is established worldwide although
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frequencies vary largely between studies [12, 15]. Of indi-
vidual species M. szulgai, M. abscessus, M. malmoense, M.
kansasii, M. intracellulare and M. avium were clinically
relevant in more than 50% of cases, suggesting a higher
pathogenic potential than other species (Fig. 4). Compared
to a Dutch study by Van Ingen et al., there are several
similarities but also some differences [23]. Our M. absces-
sus and M. intracellulare isolates were more frequently
considered clinically relevant than their Dutch counter-
parts (91.6% versus 33 and 64% versus 12.5%). In our co-
hort M. intracellulare had a higher probability of clinical
relevance than M. avium (64 and 54.2% respectively) in
contrast to the Dutch report (12.5 and 40.7%) [23]. Our
findings, however, are in line with other reports about a
higher pathogenicity of M. intracellulare [15, 38]. These
differences support the hypothesis of regional variation
and illustrate the value of local data.
Clinical relevance varies not only by species but also by
radiological presentation. Clinically significant isolates of
M. kansasii,M. malmoense andM. xenopimostly presented
with fibrocavitary changes while M. abscessus and MAC re-
lated NTM-PD more often presented with nodular bronch-
iectatic changes, which has already been described [39–41].
Our findings corroborate previous suggestions that when
assessing NTM clinical relevance, integration of radiological
findings and species identification is useful [39, 40].
Our study has several limitations inherent to the retro-
spective study design. Selection bias cannot be excluded
since data were collected from three major reference
centres receiving the more complex cases. Additionally,
increased awareness over time and more intense surveil-
lance protocols for patients with pulmonary disease may
have led to overestimation of NTM-PD risk. Our data
are limited in scope, hence caution is warranted in gen-
eralising the findings. The lack of outcome data limit the
predictive value of clinical significance.
Conclusion
NTM are widely distributed environmental opportunistic
pathogens which can cause significant morbidity and
mortality especially in patient with underlying pulmonary
conditions. In our cohort MAC species were the most fre-
quently isolated, but M. abscessus and M. malmoense had a
higher ratio of being clinically relevant when isolated. Be-
cause of geographical differences in isolates and clinical
relevance between species, it is important to acknowledge
local epidemiology as these data can be complimentary to
the ATS/IDSA criteria in assisting clinicians in their treat-
ment decision. Based on our study results, we suggest an
added value for the AFB staining results, species identifica-
tion and chest CT findings in the clinical decision-making
process. Large multicentre prospective studies with stan-
dardized microbiological detection methods and clinical
assessment reporting tools are highly needed.
Abbreviations
AFB: Acid-fast bacilli; ATS: American Thoracic Society; CF: Cystic fibrosis; CI
95%: 95% confidence interval; COPD: Chronic obstructive pulmonary disease;
HIV: Human immunodeficiency virus; IDSA: Infectious Diseases Society of
America; IQR: Interquartile ranges; MAC: Mycobacterium avium complex;
MTBc: Mycobacterium tuberculosis complex; NTM: Non-tuberculous
mycobacteria; NTM-PD: Non-tuberculous mycobacterial pulmonary disease;
OR: Odds ratio
Acknowledgements
We sincerely thank Jakko van Ingen (Radboud UMC Nijmegen) for reviewing
and discussing our data.
Authors’ contributions
YVDW (corresponding author): data gathering, analysis of data, writing of
manuscript, figures, implementation of reviewers’ remarks, preparation and
submission of initial and revised manuscript. NC: data gathering, analysis of
data, writing of manuscript. PB: ethics approval ZNA Stuivenberg, data
gathering, critical review of manuscript. TC: data gathering, analysis of data,
review of manuscript. EA: data gathering, critical review of manuscript. JB:
data gathering, critical review of manuscript. EVB: ethics approval Ghent
University Hospital, review of data analysis, multiple reviews of manuscript.
NL: ethics approval central committee University Hospitals Leuven, review of
data analysis and multivariate analysis, multiple reviews of manuscript. All
authors read and approved the final manuscript.
Funding
No funding or grants were allocated to this study.
Availability of data and materials
The dataset used and/analysed during the current study is available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
University Hospitals Leuven




Ethics Committee of the Ghent University Hospital, Belgium
Approval code: EC/2018/0356
ZNA Stuivenberg
Commissie voor Medische Ethiek ZNA – Institutional Review Board ZNA/
OCMW Antwerpen, Belgium:
Approval code: 5064
Statement on the need for informed consent:
The need for informed consent was waived because of the exclusively
retrospective nature of the study. Non-tuberculous mycobacteria are fre-
quently isolated from respiratory samples as they are ubiquitous in the envir-
onment and often not related to pathology. Some people might have been
unaware of insignificant NTM positive isolates and asking for consent might
have caused unnecessary distress and unease. Some patients included, had
already died, mostly of other causes and asking consent to the next of kin
might have caused additional, unnecessary distress and sorrow. Furthermore,
data were analysed anonymously.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Respiratory Medicine, Ghent University Hospital, Corneel
Heymanslaan 10, B9000 Ghent, Belgium. 2Department of Respiratory
Diseases, University Hospitals Leuven, Herestraat 49, B3000 Leuven, Belgium.
3Department of Pneumology, Antwerp Hospital Network Stuivenberg, Lange
Beeldekensstraat 267, B2060 Antwerp, Belgium. 4Department of Laboratory
Medicine, Department of Clinical Chemistry, Microbiology and Immunology,
Ghent University Hospital, Corneel Heymanslaan 10, B9000 Ghent, Belgium.
5Laboratory of Clinical Bacteriology and Mycology, Department of
Microbiology, Immunology and Transplantation, University Hospitals Leuven,
Herestraat 49, Leuven B3000, Belgium.
Vande Weygaerde et al. BMC Infectious Diseases         (2019) 19:1061 Page 9 of 10
Received: 23 August 2019 Accepted: 29 November 2019
References
1. Falkinham JO. Environmental sources of nontuberculous mycobacteria. Clin
Chest Med. 2015;36:35–41.
2. Gebert MJ, Delgado-Baquerizo M, Oliverio AM, Webster TM, Nichols LM,
Honda JR, et al. Ecological analyses of mycobacteria in showerhead biofilms
and their relevance to human health. MBio. 2018;9:1–15.
3. Gupta RS, Lo B, Son J. Phylogenomics and comparative genomic studies
robustly support division of the genus Mycobacterium into an emended
genus Mycobacterium and four novel genera. Front Microbiol. 2018;9:67.
4. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of
nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;
175:367–416.
5. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British
Thoracic Society guidelines for the management of non-tuberculous
mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1 LP–ii64.
6. Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, et al.
Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and
prognostic factors. Am J Respir Crit Care Med. 2010;181:514–21.
7. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US
Cystic Fibrosis Foundation and European cystic fibrosis society consensus
recommendations for the management of non-tuberculous mycobacteria in
individuals with cystic fibrosis. Thorax. 2016;71:i1–22.
8. Marras TK, Campitelli MA, Kwong JC, Lu H, Brode SK, Marchand-Austin A,
et al. Risk of nontuberculous mycobacterial pulmonary disease with
obstructive lung disease. Eur Respir J. 2016;48:928–31.
9. Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in
immunosuppressed hosts. Clin Chest Med. 2015;36:91–9.
10. Adjemian J, Olivier KN, Prevots DR. Epidemiology of pulmonary
Nontuberculous mycobacterial sputum positivity in patients with
cystic fibrosis in the United States, 2010-2014. Ann Am Thorac Soc.
2018;15:817–26.
11. Ringshausen FC, Wagner D, de Roux A, Diel R, Hohmann D, Hickstein L,
et al. Prevalence of Nontuberculous mycobacterial pulmonary disease,
Germany, 2009–2014. Emerg Infect Dis. 2016;22:1102–5.
12. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with
Nontuberculous mycobacteria. Clin Chest Med. 2015;36:13–34.
13. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB.
Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-
2010. Emerg Infect Dis. 2013;19:1889–91.
14. Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN, Zelazny A, et al.
Epidemiology of Nontuberculous mycobacterial lung disease and
tuberculosis, Hawaii, USA. Emerg Infect Dis. 2017;23:439–47.
15. Zweijpfenning S, Ingen J, Hoefsloot W. Geographic distribution of
Nontuberculous mycobacteria isolated from clinical specimens: a systematic
review. Semin Respir Crit Care Med. 2018;39:336–42.
16. van Ingen J, Hoefsloot W, Dekhuijzen PNR, Boeree MJ, van Soolingen D. The
changing pattern of clinical Mycobacterium avium isolation in the
Netherlands. Int J Tuberc Lung Dis. 2010;14:1176–80.
17. Soetaert K, Subissi L, Ceyssens P-J, Vanfleteren B, Chantrenne M, Asikainen T,
et al. Strong increase of true and false positive mycobacterial cultures sent
to the National Reference Centre in Belgium, 2007 to 2016. Eurosurveillance.
2019;24:2015–9.
18. Hoefsloot W, Van Ingen J, Andrejak C, Ängeby K, Bauriaud R, Bemer P,
et al. The geographic diversity of nontuberculous mycobacteria isolated
from pulmonary samples: an NTM-NET collaborative study. Eur Respir J.
2013;42:1604–13.
19. Thomson RM. NTM working group at Queensland TB control Centre
and Queensland mycobacterial reference laboratory. Changing
epidemiology of pulmonary nontuberculous mycobacteria infections.
Emerg Infect Dis. 2010;16:1576–83.
20. Koh W-J, Chang B, Jeong B-H, Jeon K, Kim S-Y, Lee NY, et al. Increasing
recovery of Nontuberculous mycobacteria from respiratory specimens over
a 10-year period in a tertiary referral Hospital in South Korea. Tuberc Respir
Dis (Seoul). 2013;75:199–204.
21. Kim N, Yi J, Chang CL. Recovery rates of non-Tuberculous mycobacteria
from clinical specimens are increasing in Korean tertiary-care hospitals. J
Korean Med Sci. 2017;32:1263–7.
22. Soetaert K, Vluggen C, André E, Vanhoof R, Vanfleteren B, Mathys V.
Frequency of Mycobacterium chimaera among Belgian patients, 2015. J
Med Microbiol. 2016;65:1307–10.
23. Van Ingen J, Bendien SA, De Lange WCM, Hoefsloot W, Dekhuijzen PNR,
Boeree MJ, et al. Clinical relevance of non-tuberculous mycobacteria isolated in
the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64:502–6.
24. Hermansen TS, Ravn P, Svensson E, Lillebaek T. Nontuberculous
mycobacteria in Denmark , incidence and clinical importance during the
last quarter- century. Sci Rep. 2017;7:6696.
25. Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, et al.
Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise
in non-tuberculous mycobacteria incidence in England, Wales and Northern
Ireland, 2007-2012. BMC Infect Dis. 2016;16:1–6.
26. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of
nontuberculous mycobacterial lung disease in U.S. medicare beneficiaries.
Am J Respir Crit Care Med. 2012;185:881–6.
27. Schiff HF, Jones S, Achaiah A, Pereira A, Stait G, Green B. Clinical relevance
of non-tuberculous mycobacteria isolated from respiratory specimens: seven
year experience in a UK hospital. Sci Rep. 2019;9:1730.
28. Koh W-J, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance
of nontuberculous mycobacteria isolated from respiratory specimens in
Korea. Chest. 2006;129:341–8.
29. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA,
et al. Adult patients with bronchiectasis. Chest. 2017;151:982–92.
30. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y.
Prognostic factors of 634 HIV-negative patients with Mycobacterium avium
complex lung disease. Am J Respir Crit Care Med. 2012;185:575–83.
31. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW.
Chronic respiratory disease, inhaled corticosteroids and risk of non-
tuberculous mycobacteriosis. Thorax. 2013;68:256–62.
32. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, et al. Predictors of 5-
year mortality in pulmonary Mycobacterium avium-intracellulare complex
disease. Int J Tuberc Lung Dis. 2012;16:408–14.
33. Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium
avium complex lung disease in untreated patients with stable course.
Eur Respir J. 2017;49(3).
34. Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous
mycobacterial disease and Aspergillus-related lung disease in bronchiectasis.
Eur Respir J. 2006;28:352–7.
35. Provoost J, Valour F, Gamondes D, Roux S, Freymond N, Perrot E, et al. A
retrospective study of factors associated with treatment decision for
nontuberculous mycobacterial lung disease in adults without altered
systemic immunity. BMC Infect Dis. 2018;18:659.
36. Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ,
Magis-Escurra C, et al. Nontuberculous mycobacterial pulmonary
disease and Aspergillus co-infection: Bonnie and Clyde? Eur Respir J.
2019;54:1900117.
37. Martín-Casabona N, Bahrmand AR, Bennedsen J, Østergaard Thomsen V,
Curcio M, Fauville-Dufaux M, et al. Non-tuberculous mycobacteria: patterns
of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis.
2004;8:1186–93.
38. Boyle DP, Zembower TR, Reddy S, Qi C. Comparison of clinical features,
virulence, and relapse among Mycobacterium avium complex species. Am J
Respir Crit Care Med. 2015;191:1310–7.
39. Matveychuk A, Fuks L, Priess R, Hahim I, Shitrit D. Clinical and radiological
features of Mycobacterium kansasii and other NTM infections. Respir Med.
2012;106:1472–7.
40. Koh W-J, Lee KS, Kwon OJ, Jeong YJ, Kwak S-H, Kim TS. Bilateral
bronchiectasis and bronchiolitis at thin-section CT: diagnostic
implications in nontuberculous mycobacterial pulmonary infection.
Radiology. 2005;235:282–8.
41. Marras TK, Wagnetz U, Jamieson FB, Patsios DA. Chest computed
tomography predicts microbiological burden and symptoms in pulmonary
Mycobacterium xenopi. Respirology. 2013;18:92–101.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Vande Weygaerde et al. BMC Infectious Diseases         (2019) 19:1061 Page 10 of 10
